Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.
3 reports, 2 independent
Updated Sep 19
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Congress and the Senate are considering legislation affecting FDA submissions and drug patent rights.Sub-event
Policymakers are considering changes to patent rights and market entry requirements for biotech products.1 source
Keep exploring
Part of
Congress considered proposals to strengthen FDA authority regarding medical device regulation and minimum standards.Also in this story
- Bills were introduced in the House and Senate to address agency modernization and public health standards.
- A bill was introduced on July 17th to strengthen oversight of the FDA, involving Ron Wyden.
The entities involved
Related events
- New FDA rule threatens the ability to import medicines.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Litigation regarding FDA approval process.
- PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.